Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 6:46:126686.
doi: 10.1016/j.vaccine.2024.126686. Epub 2025 Jan 5.

Meeting summary: Global vaccine and immunization research forum, 2023

Birgitte Giersing  1 , Annie X Mo  2 , Angela Hwang  3 , Shahida Baqar  4 , Kristen Earle  5 , Andrew Ford  6 , Carolyn Deal  7 , Peter Dull  8 , Martin Friede  9 , B Fenton Hall  10
Affiliations
Review

Meeting summary: Global vaccine and immunization research forum, 2023

Birgitte Giersing et al. Vaccine. .

Abstract

At the 2023 Global Vaccine and Immunization Research Forum (GVIRF), researchers from around the world gathered in the Republic of Korea to discuss advances and opportunities in vaccines and immunization. Many stakeholders are applying the lessons of Covid-19 to future emergencies, by advancing early-stage development of prototype vaccines to accelerate response to the next emerging infectious disease, and by building regional vaccine research, development, and manufacturing capacity to speed equitable access to vaccines in the next emergency. Recent vaccine licensures include: respiratory syncytial virus vaccines, both for the elderly and to protect infants through maternal immunization; a new dengue virus vaccine; and licensure of Covid-19 vaccines previously marketed under emergency use authorizations. Malaria vaccine implementation is expanding and a second malaria vaccine has been recommended by the World Health Organization. In a setback for human immunodeficiency virus vaccine development, the only remaining Phase 3 trial has been discontinued. In immunization, greater clarity is emerging on the challenges of achieving access and equity, along with strategies to address those challenges. A better understanding of behavioral and social determinants of vaccine uptake and a validated toolkit for measuring and modifying the drivers of vaccination is informing program design and service delivery, contributing to improved uptake. Implementation research, which has been essential for human papillomavirus and malaria vaccine delivery, will be critical for delivering the new respiratory syncytial virus vaccines and for many other vaccines currently in development. The growing diversity of vaccines and complexity of immunization programs are leading to greater interest in simplified regimens, combination vaccines, and other innovations to facilitate delivery. Collaboration emerged as the unifying theme of GVIRF 2023, underscoring that the combined efforts of many contributors have enabled progress thus far, and going forward will continue to be essential to ensure equitable access to vaccines for all.

Trial registration: ClinicalTrials.gov NCT04975178 NCT04351685 NCT03152903.

Keywords: GVIRF; IA2030; Immunization agenda 2030.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Birgitte Giersing and Martin Friede report financial support was provided by Bill & Melinda Gates Foundation. Angela Hwang reports financial support and travel were provided by Bill & Melinda Gates Foundation. Annie X. Mo, Shahida Baqar, Andrew Ford, Carolyn Deal, and B. Fenton Hall report relationships with the National Institute of Allergy and Infectious Diseases that include: employment and travel reimbursement. Birgitte Giersing and Martin Friede report relationships with the World Health Organization that include: employment and travel reimbursement. Kristen Earle and Peter Dull report relationships with the Bill & Melinda Gates Foundation that include: employment and travel reimbursement. Angela Hwang reports a relationship with World Health Organization that includes: consulting or advisory and travel reimbursement. WHO receives grant funding related to developing guidance for a number of vaccines referred to in the manuscript. (BG and MF) NIAID is a leading supporter of vaccine R&D, however the co-authors employed by NIAID have no conflicts of interest in their routine course of employment. (AXM, SB, AF, CD, BFH).

Figures

Figure 1
Figure 1
Behavioral and social drivers of vaccination – a measurement framework.
See this image and copyright information in PMC

References

    1. https://www.who.int/teams/immunization-vaccines-and-biologicals/strategi... World Health Organization. Explaining the Immunization Agenda 2030 n.d. (accessed October 29, 2024)
    1. US Food and Drug Administration . FDA approves first vaccine to prevent disease caused by chikungunya virus. FDA. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-v... [accessed February 7, 2024]
    1. World Health Organization . Progress and Challenges with Achieving Universal Immunization Coverage: 2023 WHO/UNICEF Estimates of National Immunization Coverage. 2024. https://cdn.who.int/media/docs/default-source/immunization/wuenic-progre... [Accessed 18 July 2023]
    1. https://www.who.int/publications-detail-redirect/9789240062726 World Health Organization. Global Vaccine Market Report 2022: a shared understanding for equitable access to vaccines. 2023. (accessed July 10, 2023)
    1. Mathieu E., Ritchie H., Rodés-Guirao L., Appel C., Giattino C., Hasell J., et al. Coronavirus (COVID-19) Vaccinations. 2020. https://ourworldindata.org/covid-vaccinations

Publication types

Associated data